A phase 1b study of Trebananib plus Paclitaxel and Trastuzumab or Capecitabine and Lapatinib in patients with HER2+ locally recurrent or metastatic breast cancer
Year: 2015
Type: conference-paper
Source: ORBi (University of Liège)
Authors: Peter A. Kaufman, Gilles Freyer, Margaret Kemeny, Anthony Gonçalvès, Guy Jérusalem, Alison Stopeck, N. Vrindavanam, Florence Dalenc, Nadeeshani Nanayakkara, Benjamin Wu, Cheryl A. Pickett, Hans Wildiers
Institutions: Dartmouth–Hitchcock Medical Center, Dartmouth Cancer Center, Hôpital Lyon Sud, New York Hospital Queens, Institut Paoli-Calmettes, Centre Hospitalier Universitaire de Liège, University of Arizona, Institut Claudius Regaud, IQVIA (United States), Amgen (United States), Universitair Ziekenhuis Leuven
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2295206420